XML 56 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Note 2 - Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2020
Revenue $ 184,335,000 $ 133,937,000 $ 117,687,000
Consumables [Member] | Transferred at Point in Time [Member]      
Revenue 91,808,000 63,009,000 53,311,000
Hardware and Software [Member] | Transferred at Point in Time [Member]      
Revenue 57,614,000 44,019,000 40,090,000
Service [Member]      
Revenue 34,913,000 26,909,000 24,286,000
Service [Member] | Transferred at Point in Time [Member]      
Revenue 19,097,000 15,626,000 14,936,000
Service [Member] | Transferred over Time [Member]      
Revenue   11,283,000  
Services and Software [Member] | Transferred over Time [Member]      
Revenue 15,816,000   9,350,000
Operating Segments [Member]      
Revenue 184,335 133,937 115,224
Corporate, Non-Segment [Member]      
Revenue [1],[2] 0 0 2,463,000
Corporate, Non-Segment [Member] | Consumables [Member] | Transferred at Point in Time [Member]      
Revenue     2,436,000
Corporate, Non-Segment [Member] | Service [Member] | Transferred at Point in Time [Member]      
Revenue     27,000
Sterilization and Disinfection Control [Member] | Operating Segments [Member]      
Revenue [1] 59,044,000 53,119,000 49,660,000
Sterilization and Disinfection Control [Member] | Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member]      
Revenue 50,311,000 45,869,000 42,654,000
Sterilization and Disinfection Control [Member] | Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member]      
Revenue 700,000 505,000 551,000
Sterilization and Disinfection Control [Member] | Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member]      
Revenue 2,225,000 1,848,000 1,592,000
Sterilization and Disinfection Control [Member] | Operating Segments [Member] | Service [Member] | Transferred over Time [Member]      
Revenue   4,897,000  
Sterilization and Disinfection Control [Member] | Operating Segments [Member] | Services and Software [Member] | Transferred over Time [Member]      
Revenue 5,808,000   4,863,000
Biopharmaceutical Development [Member] | Operating Segments [Member]      
Revenue [1] 45,579,000 33,892,000 13,851,000 [3]
Biopharmaceutical Development [Member] | Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member]      
Revenue 15,551,000 13,942,000 4,981,000 [3]
Biopharmaceutical Development [Member] | Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member]      
Revenue 21,651,000 13,545,000 6,015,000 [3]
Biopharmaceutical Development [Member] | Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member]      
Revenue 3,864,000 2,928,000 1,761,000 [3]
Biopharmaceutical Development [Member] | Operating Segments [Member] | Service [Member] | Transferred over Time [Member]      
Revenue   3,477,000  
Biopharmaceutical Development [Member] | Operating Segments [Member] | Services and Software [Member] | Transferred over Time [Member]      
Revenue 4,513,000   1,094,000 [3]
Calibration Solutions [Member] | Operating Segments [Member]      
Revenue [1] 46,872,000 46,926,000 51,713,000
Calibration Solutions [Member] | Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member]      
Revenue 3,675,000 3,198,000 3,240,000
Calibration Solutions [Member] | Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member]      
Revenue 28,537,000 29,969,000 33,524,000
Calibration Solutions [Member] | Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member]      
Revenue 11,212,000 10,850,000 11,556,000
Calibration Solutions [Member] | Operating Segments [Member] | Service [Member] | Transferred over Time [Member]      
Revenue   2,909,000  
Calibration Solutions [Member] | Operating Segments [Member] | Services and Software [Member] | Transferred over Time [Member]      
Revenue 3,448,000   3,393,000
Clinical Genomics [Member] | Operating Segments [Member]      
Revenue [1] 32,840,000 [4] $ 0 $ 0
Clinical Genomics [Member] | Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member]      
Revenue 22,271,000    
Clinical Genomics [Member] | Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member]      
Revenue [4] 6,726,000    
Clinical Genomics [Member] | Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member]      
Revenue [4] 1,796,000    
Clinical Genomics [Member] | Operating Segments [Member] | Services and Software [Member] | Transferred over Time [Member]      
Revenue [4] $ 2,047,000    
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
[2] Non-reportable operating segments (including our Cold Chain Packaging Division which ceased operations during the year ended March 31, 2020) and unallocated corporate expenses are reported within Corporate and Other.
[3] Revenues in the Biopharmaceutical Development division represent transactions subsequent to the acquisition of Gyros Protein Technologies Holding AB on October 31, 2019.
[4] Revenues in the Clinical Genomics division represent transactions subsequent to the Agena Acquisition on October 20, 2021.